OS Therapies (OSTX)
Develops Listeria immunotherapy for recurrent metastatic osteosarcoma after surgery.
$1.75
Pre-market+0.04 (+2.04%)
At close$1.72(+3.31%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions30 holders · as of Jun 30, 2026 | 6.28% | 2.90M shares | |
| Otherremainder | 93.72% | 43.23M shares |
46.13M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Institutions13F, as of Jun 30, 2026
30 holders · 2.90M shares · 6 new positions · 21 increased · 4 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 777.7K | 1.69% | +308.2K | Aug 13, 2026 |
| CM Management, LLC | 400.0K | 0.87% | 0 | Aug 13, 2026 |
| Geode Capital Management, LLC | 301.8K | 0.65% | +21.7K | Aug 12, 2026 |
| Howard Financial Services, Ltd. | 248.0K | 0.54% | +2.6K | Jul 7, 2026 |
| BlackRock, Inc. | 242.5K | 0.53% | +177.7K | Aug 7, 2026 |
| Vanguard Fiduciary Trust Co | 174.1K | 0.38% | +57.5K | Aug 13, 2026 |
| State Street Corp | 120.1K | 0.26% | +28.9K | Aug 7, 2026 |
| Marshall Wace, LLP | 100.6K | 0.22% | +100.6K | Aug 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Ayala Pharmaceuticals, Inc. | 9.99% | 2.16M | 13G | Apr 16, 2025 ↗ |
| Thomas A. Satterfield, Jr. | 9.40% | 3.12M | 13G | Aug 13, 2025 ↗ |
| Shalom Auerbach | 8.50% | 2.68M | 13D | Aug 18, 2025 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.
